SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:229a2173-d921-4a10-b0ec-29dd517d764b"
 

Search: onr:"swepub:oai:lup.lub.lu.se:229a2173-d921-4a10-b0ec-29dd517d764b" > Octreotide SC depot...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Pavel, MarianneCharité - University Medicine Berlin,Friedrich-Alexander University Erlangen-Nürnberg (author)

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors : a phase 2, multicenter study

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2018-12-08
  • Springer Science and Business Media LLC,2019

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:229a2173-d921-4a10-b0ec-29dd517d764b
  • https://lup.lub.lu.se/record/229a2173-d921-4a10-b0ec-29dd517d764bURI
  • https://doi.org/10.1007/s00280-018-3734-1DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Purpose: Octreotide SC depot is a novel, ready-to-use formulation administered via a thin needle. In a phase 1 study in healthy volunteers, this formulation provided higher bioavailability of octreotide with faster onset and stronger suppression of IGF-1 in healthy volunteers versus long-acting intramuscular (IM) octreotide. This phase 2 study evaluated the pharmacokinetics, efficacy, and safety of octreotide SC depot in patients with acromegaly and functioning NETs, previously treated with octreotide IM. Methods: Adult patients with acromegaly or functioning NETs treated for ≥ 2 months with octreotide IM [10/20/30 mg every 4 weeks (q4w)] received the last dose of octreotide IM treatment in study period 0 and were randomized 28 days later to receive octreotide SC depot 10 mg q2w, or 20 mg q4w for 3 months (period 1). The primary objective was to characterize the PK profile of octreotide SC depot after each injection vs PK for octreotide IM (period 0). Results: Twelve patients were randomized to receive octreotide SC depot 10 mg q2w (acromegaly n = 3; NET n = 1) or 20 mg q4w (acromegaly n = 4; NET n = 4). Plasma levels of octreotide were higher with octreotide SC depot as compared to octreotide IM. Adverse events were reported in 6 and 8 patients during period 0 and period 1, respectively; most common in period 1 were gastrointestinal disorders. Conclusion: Octreotide SC depot provided higher exposure (AUC) than octreotide IM, maintained biochemical control in patients with acromegaly and symptom control in patients with functioning NETs, and was well tolerated with a safety profile consistent with octreotide IM. ClinicalTrials.gov identifier: NCT02299089.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Borson-Chazot, FrançoiseClaude Bernard University Lyon 1 (author)
  • Cailleux, AnneHopital Charles Nicolle (author)
  • Hörsch, DieterCentral Clinic Bad Berka (author)
  • Lahner, HaraldUniversity Hospital Essen (author)
  • Pivonello, RosarioUniversity of Naples Federico II (author)
  • Tauchmanova, LibuseNovartis Pharma AG (author)
  • Darstein, ChristelleNovartis Pharma AG (author)
  • Olsson, HåkanCamurus AB (author)
  • Tiberg, FredrikLund University,Lunds universitet,Fysikalisk kemi,Enheten för fysikalisk och teoretisk kemi,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Physical Chemistry,Physical and theoretical chemistry,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH,Camurus AB(Swepub:lu)fk1-fti (author)
  • Ferone, DiegoUniversity of Genoa,Ospedale Policlinico San Martino (author)
  • Charité - University Medicine BerlinFriedrich-Alexander University Erlangen-Nürnberg (creator_code:org_t)

Related titles

  • In:Cancer Chemotherapy and Pharmacology: Springer Science and Business Media LLC83:2, s. 375-3850344-57041432-0843

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view